1. Home
  2. CNOBP vs WGSWW Comparison

CNOBP vs WGSWW Comparison

Compare CNOBP & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ConnectOne Bancorp Inc.

CNOBP

ConnectOne Bancorp Inc.

N/A

Current Price

$24.41

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Logo GeneDx Holdings Corp.

WGSWW

GeneDx Holdings Corp.

N/A

Current Price

$0.01

Market Cap

0.0

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
CNOBP
WGSWW
Founded
N/A
2017
Country
United States
United States
Employees
493
1300
Industry
Major Banks
Retail: Computer Software & Peripheral Equipment
Sector
Finance
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CNOBP
WGSWW
Price
$24.41
$0.01
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.6K
106.4K
Earning Date
N/A
02-18-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$305,450,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
50.79
52 Week Low
$20.75
$0.00
52 Week High
$24.85
$0.23

Technical Indicators

Market Signals
Indicator
CNOBP
WGSWW
Relative Strength Index (RSI) 54.04 42.82
Support Level $24.42 $0.01
Resistance Level $24.84 $0.02
Average True Range (ATR) 0.16 0.00
MACD 0.00 0.00
Stochastic Oscillator 70.83 29.75

Price Performance

Historical Comparison
CNOBP
WGSWW

About CNOBP ConnectOne Bancorp Inc.

ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.

About WGSWW GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: